Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
PLUS vs DBD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PLUS Captures Overall Composite Edge (47.6 HOLD vs 50.6 HOLD), While DBD Leads 4–2 on Growth & Valuation Pillars
PLUS Overall Winner
6-Pillar Tally: PLUS 2 – 4 DBD
Matrix Metrics: PLUS 7 – 3 DBD
As of Nov 20, 2026, ePlus Inc (PLUS) captures the overall head-to-head institutional edge over Diebold Nixdorf, Incorporated (DBD) on higher Unified Composite conviction (47.6/100 HOLD vs. 50.6/100 HOLD) after splitting the core matrix 7–3 (led by Growth & Scale, R&D & Supply-Chain Moat), while DBD wins 4–2 across the 6-pillar growth and valuation breakdown. PLUS trades at $92.13 (16.6x Forward P/E, 6.8% operating margin) versus DBD at $51.86 (8.4x Forward P/E, 9.0% operating margin).
- Composite vs. Pillar Nuance: While DBD currently prints a higher short-term Unified Composite Score (50.6/100 HOLD vs. PLUS 47.6/100 HOLD), PLUS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (6.8% vs. 9.0% operating margin) and revenue trajectory (+9.7% vs. +5.2% YoY).
- Technical & Structure Timing Caution: PLUS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.2); meanwhile DBD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About PLUS vs DBD
PLUS
Head-to-Head Winner
ePlus Inc
$92.13
-3.67% 1D
Market Cap
$2.5B
TTM Revenue
$2.51B
Forward P/E
16.6x
Beta / 30D Vol
0.89β · 58% Vol
Unified Composite Score
47.6
HOLD
Tech 47.0
Fund 44.0
Flow 55.0
Mom 30.9
Weinstein Technical Phase
Neutral · Hold
DBD
Diebold Nixdorf, Incorporated
$51.86
+3.16% 1D
Market Cap
$1.7B
TTM Revenue
$3.92B
Forward P/E
8.4x
Beta / 30D Vol
0.91β · 60% Vol
Unified Composite Score
50.6
HOLD
Tech 58.0
Fund 59.0
Flow 67.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (PLUS 2 – 4 DBD)
1. Valuation Multiples
DBD
Forward P/E
16.6x
8.4x
Trailing P/E
20.1x
23.8x
PEG Ratio
1.18x
N/M
EV / Revenue
0.9x
0.6x
2. Growth & Scale
PLUS
Revenue Growth (YoY)
+9.7%
+5.2%
Earnings Growth (YoY)
+18.0%
-82.9%
TTM Revenue (USD)
$2.51B
$3.92B
Market Cap
$2.5B
$1.7B
3. Profitability & Quality
DBD
Gross Margin
25.2%
26.0%
Operating Margin
6.8%
9.0%
Net Profit Margin
5.0%
2.0%
Return on Equity (ROE)
11.6%
7.7%
4. Balance Sheet & Cash Flow
DBD
Cash Generation (TTM)
$32M
$127M
Cash Flow Margin
1.3%
3.2%
Net Cash / Leverage
$242M Net Cash
$764M Net Debt (1.01x D/E)
Dividend Yield
1.07%
None (0.00%)
5. Options & Positioning
DBD
Options Structure Phase
CONSOLIDATION
BREAKDOWN
Current IV / %ile
173.5% (100th %ile)
38.9% (9th %ile)
Put/Call OI Skew
N/A
1.24x (Put-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
PLUS
OpEx & R&D Intensity
18.4% of Rev ($461M)
17.0% of Rev ($667M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Software - Application Operator
Software - Application Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PLUS (7) vs DBD (3)| Institutional Metric | PLUS | DBD | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.5B | $1.7B | PLUS | |
| Trailing P/E Ratio | 20.1x | 23.8x | PLUS | |
| Forward P/E Ratio | 16.6x | 8.4x | DBD | |
| Revenue Growth (YoY) | +9.7% | +5.2% | PLUS | |
| Operating Margin (TTM) | 6.8% | 9.0% | DBD | |
| Net Profit Margin | 5.0% | 2.0% | PLUS | |
| Return on Equity (ROE) | 11.6% | 7.7% | PLUS | |
| 52-Week Range Position | 72% ($73–$100) | 5% ($50–$92) | PLUS | |
| Beta / 30D Volatility | 0.89β · 58% Vol | 0.91β · 60% Vol | PLUS | |
| Unified Institutional Score | 47.6 / 100 (HOLD) | 50.6 / 100 (HOLD) | DBD | |
| Trailing 12M Revenue (USD) | $2.51B | $3.92B | Scale | |
| Gross Profit Margin (TTM) | 25.2% | 26.0% | Quality | |
| PEG Ratio & EV / Revenue | 1.18x PEG · 0.9x EV/Rev | N/M PEG · 0.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $32M ($242M Net Cash) | $127M ($764M Net Debt (1.01x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PLUS +20.94 pp
3M Horizon
PLUS +31.43 pp
6M Horizon
PLUS +38.12 pp
1Y Horizon
PLUS +19.73 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PLUS Revenue | DBD Revenue | PLUS Op. Margin | DBD Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $1.37B | $4.41B | 5.8% | -0.6% | PLUS |
| FY2020 | $1.59B | $3.90B | 6.0% | 0.6% | PLUS |
| FY2021 | $1.57B | $3.91B | 6.8% | 3.5% | PLUS |
| FY2022 | $1.82B | $3.46B | 8.1% | -6.1% | PLUS |
| FY2023 | $2.07B | N/A | 8.0% | N/A | PLUS |
| FY2024 | $2.18B | $3.75B | 6.1% | 4.9% | PLUS |
| FY2025 | $2.00B | $3.81B | 5.0% | 6.4% | DBD |
| FY2026 | $2.44B | N/A | 6.8% | N/A | PLUS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
PLUS
CONSOLIDATION
Current IV
173.5%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact PLUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DBD
BREAKDOWN
Current IV
38.9%
IV Percentile
9th %ile
Put/Call OI Skew
1.24x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact DBD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
PLUS Moat Profile
Cyclical / Execution-Driven Positioning
Software - Application Operator
OpEx & R&D Reinvestment
18.4% of Rev ($461M)
90D Engineering Disclosures
0 Published
DBD Moat Profile
Cyclical / Execution-Driven Positioning
Software - Application Operator
OpEx & R&D Reinvestment
17.0% of Rev ($667M)
90D Engineering Disclosures
0 Published
Investor FAQ PLUS vs DBD Key Questions & Quantitative Answers
As of Nov 20, 2026, ePlus Inc (PLUS) captures the overall head-to-head institutional edge over Diebold Nixdorf, Incorporated (DBD) on higher Unified Composite conviction (47.6/100 HOLD vs. 50.6/100 HOLD) after splitting the core matrix 7–3 (led by Growth & Scale, R&D & Supply-Chain Moat), while DBD wins 4–2 across the 6-pillar growth and valuation breakdown. PLUS trades at $92.13 (16.6x Forward P/E, 6.8% operating margin) versus DBD at $51.86 (8.4x Forward P/E, 9.0% operating margin). Composite vs. Pillar Nuance: While DBD currently prints a higher short-term Unified Composite Score (50.6/100 HOLD vs. PLUS 47.6/100 HOLD), PLUS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (6.8% vs. 9.0% operating margin) and revenue trajectory (+9.7% vs. +5.2% YoY). Technical & Structure Timing Caution: PLUS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.2); meanwhile DBD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PLUS leads the Growth & Scale pillar: PLUS posts +9.7% YoY revenue growth and +18.0% YoY earnings growth on $2.51B TTM revenue (25.2% gross margin, 6.8% operating margin), compared with DBD at +5.2% YoY revenue growth and -82.9% YoY earnings growth on $3.92B TTM revenue (26.0% gross margin, 9.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), PLUS cumulative revenue shifted +78.1% while DBD shifted -13.6%. In operating R&D and SG&A reinvestment, PLUS deploys 18.4% of Rev ($461M) (0 90-day corporate R&D disclosures) versus 17.0% of Rev ($667M) (0 disclosures) for DBD.
DBD screens cheaper on headline valuation multiples. PLUS trades at 16.6x Forward P/E, 20.1x Trailing P/E, 1.18x PEG, and 0.9x EV/Revenue (1.3% FCF margin), whereas DBD trades at 8.4x Forward P/E, 23.8x Trailing P/E, N/M PEG, and 0.6x EV/Revenue (3.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLUS (11.6% ROE) versus DBD (7.7% ROE) capital efficiency.
In options market volatility and institutional positioning, PLUS carries 173.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.89β · 58% Vol realized risk). By comparison, DBD carries 38.9% implied volatility (9th %ile, Compressed (<25th %ile)), a 1.24x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.91β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DBD vs PLUS · Reverse Pair
PLUS vs CNXN
· Sector Peer
PLUS vs SPSC
· Sector Peer
PLUS vs MLAB
· Sector Peer
DBD vs RPM
· Sector Peer
DBD vs PBI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem